Previously submitted to: Journal of Medical Internet Research (no longer under consideration since Feb 07, 2025)
Date Submitted: Oct 23, 2024
Open Peer Review Period: Oct 30, 2024 - Dec 25, 2024
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Chatbots in healthcare: A study of readability and response accuracy in answers to questions about hypertension.
ABSTRACT
Background:
AI-powered chatbots, using Large Language Models, may effectively answer questions from patients with hypertension, providing responses that are accurate, empathetic, and easy to read.
Objective:
This study evaluates the performance of three such chatbots in delivering quality responses.
Methods:
One hundred questions were randomly selected from the Reddit forum r/hypertension and submitted to three publicly available chatbots (ChatGPT-3.5, Microsoft Copilot, Gemini), anonymized as A, B, and C. Two independent medical professionals assessed the accuracy and empathy of their responses using Likert scales. Additionally, 300 responses were analyzed with the WebFX readability tool to measure various readability indices.
Results:
In total, 300 responses were evaluated. Chatbot A generated the most extensive responses, with an average of 13 sentences per reply, while Chatbot B had the shortest replies. Chatbot C achieved the highest score on the Flesch Reading Ease Scale, indicating better readability, while Chatbot A scored the lowest. Other readability metrics, including the Flesch-Kincaid Grade Level, Gunning Fog Score, and others, also showed significant differences among the chatbots, reflecting variability in readability.
Conclusions:
The study indicates that while all chatbots can produce professional responses, their readability varies significantly. These findings underscore the potential of AI chatbots in patient education. However, they also highlight the urgent need for further optimization to enhance the comprehensibility of their outputs.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.